ECO Synthesis® siRNA (Cardiovascular Partner Program)
Cardiovascular Disease
PreclinicalActive
Key Facts
About Codexis
Founded in 2002, Codexis has pioneered the use of engineered enzymes for pharmaceutical manufacturing, with a proven track record including the scale-up of an enzyme for Pfizer's Paxlovid. The company has strategically expanded into RNA manufacturing, offering a full enzymatic synthesis platform for oligonucleotides like siRNA. Codexis operates as a partner-driven business, providing custom enzyme solutions and manufacturing services to accelerate and de-risk therapeutic development for its clients.
View full company profileTherapeutic Areas
Other Cardiovascular Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Brilinta (ticagrelor) | AstraZeneca | Approved |
| NLRP3 inhibitor | Novo Nordisk | Phase 1 |
| Lipitor | Viatris | Approved |
| Alnylam Collaboration Targets | Tenaya Therapeutics | Discovery/Research |